There were 2,015 press releases posted in the last 24 hours and 440,618 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image